Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: BIM Finally

Jessie A Brown; Adolfo Ferrando

doi:10.1016/j.ccell.2018.11.011

Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: BIM Finally

Cancer Cell. 2018 Dec 10;34(6):869-871. doi: 10.1016/j.ccell.2018.11.011.

Authors

Jessie A Brown¹, Adolfo Ferrando²

Affiliations

¹ Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
² Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA; Department of Pediatrics, Columbia University Medical Center, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10032, USA; Department of Systems Biology, Columbia University, New York, NY 10032, USA. Electronic address: af2196@columbia.edu.

PMID: 30537507
DOI: 10.1016/j.ccell.2018.11.011

Abstract

Glucocorticoid resistance represents a major challenge in treating acute lymphoblastic leukemia. In this issue of Cancer Cell, Jing and colleagues show epigenetic deregulation of glucocorticoid-induced BIM activation in glucocorticoid-resistant leukemia cells, and restore glucocorticoid-receptor-induced BIM upregulation with DNA demethylating agents to effectively enhance glucocorticoid response.

Publication types

Comment

MeSH terms

Bcl-2-Like Protein 11
Chromatin
Dexamethasone
Glucocorticoids*
Humans
Lymphocytes
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
Receptors, Glucocorticoid / genetics

Substances

Bcl-2-Like Protein 11
Chromatin
Glucocorticoids
Receptors, Glucocorticoid
Dexamethasone